KemPharm to Present at the 2nd Annual Neuroscience
Post# of 301275
CORALVILLE, Iowa, March 27, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH ), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett, Ph.D., Senior Director, Scientific Affairs, will present at the Sachs Associates 2 nd Annual Neuroscience Biopartnering and Investment Forum being held March 27, 2017, at the New York Academy of Sciences.
Details of KemPharm's presentation are as follows:
| Event: | 2 nd Annual Neuroscience Biopartnering and Investment Forum | |
| Date: | Monday, March 27, 2017 | |
| Time: | 3:20 p.m. ET | |
| Location: | New York Academy of Sciences 7 World Trade Center 250 Greenwich St., 40 th Floor (D Elevator Bank) New York, NY 10007 | |
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com .
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com jdrumm@tiberend.com Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 dcohen@kempharm.com
(0)
(0)